IN2012DN05169A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05169A IN2012DN05169A IN5169DEN2012A IN2012DN05169A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A IN 5169DEN2012 A IN5169DEN2012 A IN 5169DEN2012A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A
- Authority
- IN
- India
- Prior art keywords
- serum half
- glycovariant
- introducing
- increasing
- methods
- Prior art date
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26609509P | 2009-12-02 | 2009-12-02 | |
US32758210P | 2010-04-23 | 2010-04-23 | |
PCT/US2010/058765 WO2011068993A1 (fr) | 2009-12-02 | 2010-12-02 | Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN05169A true IN2012DN05169A (fr) | 2015-10-23 |
Family
ID=44115295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5169DEN2012 IN2012DN05169A (fr) | 2009-12-02 | 2010-12-02 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8722615B2 (fr) |
EP (1) | EP2507267B1 (fr) |
JP (1) | JP2013512674A (fr) |
KR (1) | KR20140015152A (fr) |
CN (1) | CN102770458A (fr) |
AU (1) | AU2010325943A1 (fr) |
BR (1) | BR112012013330A2 (fr) |
CA (1) | CA2782320A1 (fr) |
IN (1) | IN2012DN05169A (fr) |
RU (1) | RU2012127383A (fr) |
WO (1) | WO2011068993A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
US8883982B2 (en) * | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
RU2648157C2 (ru) * | 2012-07-18 | 2018-03-22 | Аподжиникс Аг | КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ СМЕСЬ ИЗОФОРМ CD95-Fc |
US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
WO2014144621A2 (fr) * | 2013-03-15 | 2014-09-18 | Pyranose Biotherapeutics, Inc. | Protéines de fusion de fc modifiées |
GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
ES2759252T3 (es) | 2013-10-31 | 2020-05-08 | Resolve Therapeutics Llc | Fusiones y métodos terapéuticos de nucleasa-albúmina |
WO2015114150A1 (fr) | 2014-02-02 | 2015-08-06 | Medimmune Limited | PROTÉINE CHIMÉRIQUE COMPOSÉE D'UN DOMAINE ANTAGONISTE DE NGF ET D'UN DOMAINE ANTAGONISTE DE TNFα |
AU2015237176A1 (en) * | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
WO2016069889A1 (fr) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Hybrides nucléase-transferrine à visée thérapeutique et procédés associés |
CA2980757A1 (fr) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Proteines de fusion associees a la follistatine et leurs utilisations |
EP3302532A4 (fr) | 2015-06-05 | 2019-01-09 | New York University | Compositions et procédés en rapport avec des agents biologiques antistaphylococciques |
US11866736B2 (en) | 2015-07-31 | 2024-01-09 | The General Hospital Corporation | Protein prostheses for mitochondrial diseases or conditions |
EP3374399A1 (fr) * | 2015-11-11 | 2018-09-19 | Opi Vi- IP Holdco LLC | Composition et méthodes pour anticorps anti-tnfr2 |
EP4410378A3 (fr) | 2016-07-01 | 2024-10-09 | Resolve Therapeutics, LLC | Fusions de binuclease optimisees et procedes |
KR20200039778A (ko) | 2017-08-22 | 2020-04-16 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
KR102263105B1 (ko) * | 2018-09-05 | 2021-06-09 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 |
AU2020204992A1 (en) | 2019-01-04 | 2021-07-15 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
WO2022006153A1 (fr) | 2020-06-29 | 2022-01-06 | Resolve Therapeutics, Llc | Traitement du syndrome de sjögren à l'aide de protéines de fusion de type nucléases |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005330A1 (fr) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Procede pour ameliorer la stabilite des glycoproteines |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
DK0939121T4 (da) * | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5770401A (en) | 1991-10-15 | 1998-06-23 | Mullarkey; Michael F. | Methods and compositions for treating allergic reactions |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5869337A (en) * | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) * | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
AU2207195A (en) * | 1994-04-05 | 1995-10-23 | Board Of Regents, The University Of Texas System | Modified receptors that continuously signal |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
US7094564B1 (en) * | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US5570401A (en) * | 1995-09-22 | 1996-10-29 | General Electric Company | BWR containment configuration having partitioned wetwell airspace |
DE69724451T2 (de) * | 1996-12-06 | 2004-03-18 | Amgen Inc., Thousand Oaks | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
US6265535B1 (en) * | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
WO1999011791A2 (fr) | 1997-09-05 | 1999-03-11 | University Of Washington | Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes |
WO1999011662A1 (fr) | 1997-09-05 | 1999-03-11 | Millennium Biotherapeutics, Inc. | Nouvelles molecules de la famille des proteines associees au ligand du tnfr et leurs utilisations |
CA2310575A1 (fr) * | 1997-11-07 | 1999-05-20 | Uab Research Foundation | Procede d'augmentation de l'expression genique |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
EP1054961A2 (fr) | 1998-02-17 | 2000-11-29 | Incyte Pharmaceuticals, Inc. | Proteine de la famille des recepteurs a chaine courte humains du tnf |
CN1204147C (zh) | 1998-02-25 | 2005-06-01 | 利思进药品公司 | 提高以抗体为基础的融合蛋白的循环半衰期的方法 |
ATE430149T1 (de) * | 1998-03-04 | 2009-05-15 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
JP2002511264A (ja) * | 1998-04-16 | 2002-04-16 | ジェネンテック・インコーポレーテッド | 組織プラスミノーゲン活性化因子プロ配列を使用するグリコシル化タンパク質の分泌 |
US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
ATE259829T1 (de) * | 1998-10-20 | 2004-03-15 | Vlaams Interuniv Inst Biotech | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis |
AU764479B2 (en) * | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
AU2000236029A1 (en) | 1999-02-23 | 2000-09-14 | Anne Chew | Receptor isogenes: polymorphisms in the tissue necrosis factor receptor |
US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6498165B1 (en) * | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
ES2225199T3 (es) * | 1999-08-10 | 2005-03-16 | Glaxo Group Limited | Uso de ligandos del receptor ep4 en el tratamiento del dolor neuropatico. |
PT1210411E (pt) * | 1999-08-25 | 2006-12-29 | Immunex Corp | Composições e métodos para cultura celular melhorada |
GB9927681D0 (en) | 1999-11-23 | 2000-01-19 | Glaxo Group Ltd | Protein |
CA2400214A1 (fr) | 2000-02-11 | 2001-11-15 | Amgen Inc. | Recepteur de la famille tnf |
CA2399832C (fr) * | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps |
WO2001064889A2 (fr) * | 2000-03-02 | 2001-09-07 | Xencor | CONCEPTION ET DECOUVERTE DE VARIANTS DU TNF-α A BASE DE PROTEINES DESTINES AU TRAITEMENT DES PATHOLOGIES LIEES AU TNF-$g(a) |
JP2003528149A (ja) * | 2000-03-24 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 軟骨性疾患の治療のためのインスリンの使用 |
US6800300B1 (en) * | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
DK1522590T3 (da) | 2000-06-28 | 2009-12-21 | Glycofi Inc | Fremgangsmåde til fremstilling af modificerede glykoproteiner |
EP1317536B1 (fr) | 2000-09-05 | 2009-05-13 | Amgen Inc. | Molecules analogues au recepteur du tnf et ses utilisations |
US6610750B1 (en) * | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
US20020150582A1 (en) * | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
US7157557B2 (en) * | 2001-02-23 | 2007-01-02 | Immunex Corporation | Increased recovery of active proteins |
US6972327B1 (en) * | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
EP1578771B1 (fr) * | 2001-10-10 | 2013-03-06 | Novo Nordisk A/S | Remodelage et glycoconjugaison de peptides |
WO2003040131A1 (fr) * | 2001-11-07 | 2003-05-15 | F. Hoffmann-La Roche Ag | Aminopyrimidines et aminopyridines |
WO2003059935A2 (fr) * | 2001-12-21 | 2003-07-24 | Immunex Corporation | Methodes de purification d'une proteine |
WO2003072035A2 (fr) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
SI1946776T1 (sl) * | 2002-02-27 | 2017-07-31 | Immunex Corporation | Stabiliziran tnfr-fc sestavek, ki obsega arginin |
DE10209821A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
PL376821A1 (pl) * | 2002-03-27 | 2006-01-09 | Immunex Corporation | Sposoby zwiększania produkcji polipeptydów |
US7067279B1 (en) * | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
US6974681B1 (en) * | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
US6924124B1 (en) * | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DK1572744T3 (da) | 2002-12-16 | 2010-09-20 | Genentech Inc | Immunoglobulinvarianter og deres anvendelser |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US7892563B2 (en) * | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
WO2004113387A2 (fr) | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite |
CN100509847C (zh) * | 2003-08-01 | 2009-07-08 | 安美基公司 | 结晶肿瘤坏死因子受体2多肽 |
JP2007501812A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
US7268116B2 (en) * | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
US7507745B2 (en) * | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
JP4940136B2 (ja) | 2004-06-28 | 2012-05-30 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | キメラタンパク質およびその使用 |
US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
JP2008528006A (ja) | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
WO2006083869A2 (fr) | 2005-01-31 | 2006-08-10 | Ception Therapeutics, Inc. | Inhibiteurs du facteur de necrose tumorale |
CA2612937C (fr) * | 2005-07-22 | 2014-05-06 | Amgen Inc. | Lyophilisats proteiques concentres, procedes associes et leurs utilisations |
CN1954882A (zh) | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
US7626895B2 (en) * | 2005-12-01 | 2009-12-01 | International Business Machines Corporation | Removable media battery pack for powering a media accessor of an automated data-storage library |
US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
CA2666981A1 (fr) | 2006-10-20 | 2008-05-02 | Ercole Biotech, Inc. | Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
IL182956A0 (en) | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
EP2152751A1 (fr) | 2007-05-31 | 2010-02-17 | Genmab A/S | Protéines de fusion ou liéee à demi-vie étendue |
JP2010531135A (ja) | 2007-06-04 | 2010-09-24 | ノボ ノルディスク アクティーゼルスカブ | N−アセチルグルコサミニルトランスフェラーゼを使用したo結合型グリコシル化 |
US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
CA2699944C (fr) * | 2007-09-21 | 2017-11-14 | The Regents Of The University Of California | Interferon cible manifestant des activites apoptotiques et anti-tumorales puissantes |
CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
CA2733911C (fr) * | 2008-08-14 | 2019-09-03 | Acceleron Pharma Inc. | Utilisation de pieges gdf renfermant des polypeptides de variant actriib destines a augmenter le taux de globules rouges |
WO2010033854A2 (fr) | 2008-09-19 | 2010-03-25 | Synageva Biopharma Corp. | Protéines de fusion dérivées d’une cellule aviaire |
KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
KR20190090049A (ko) * | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
US8883982B2 (en) * | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
-
2010
- 2010-12-02 RU RU2012127383/10A patent/RU2012127383A/ru not_active Application Discontinuation
- 2010-12-02 KR KR1020127017129A patent/KR20140015152A/ko not_active Application Discontinuation
- 2010-12-02 EP EP10835138.8A patent/EP2507267B1/fr active Active
- 2010-12-02 WO PCT/US2010/058765 patent/WO2011068993A1/fr active Application Filing
- 2010-12-02 IN IN5169DEN2012 patent/IN2012DN05169A/en unknown
- 2010-12-02 AU AU2010325943A patent/AU2010325943A1/en not_active Abandoned
- 2010-12-02 CA CA2782320A patent/CA2782320A1/fr not_active Abandoned
- 2010-12-02 BR BR112012013330A patent/BR112012013330A2/pt not_active IP Right Cessation
- 2010-12-02 CN CN2010800629282A patent/CN102770458A/zh active Pending
- 2010-12-02 JP JP2012542194A patent/JP2013512674A/ja not_active Withdrawn
- 2010-12-02 US US12/959,220 patent/US8722615B2/en active Active
-
2014
- 2014-04-24 US US14/261,212 patent/US20150010555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150010555A1 (en) | 2015-01-08 |
WO2011068993A1 (fr) | 2011-06-09 |
CN102770458A (zh) | 2012-11-07 |
EP2507267B1 (fr) | 2016-09-14 |
BR112012013330A2 (pt) | 2017-03-28 |
EP2507267A1 (fr) | 2012-10-10 |
EP2507267A4 (fr) | 2013-05-29 |
JP2013512674A (ja) | 2013-04-18 |
RU2012127383A (ru) | 2014-01-10 |
US8722615B2 (en) | 2014-05-13 |
AU2010325943A1 (en) | 2012-06-21 |
KR20140015152A (ko) | 2014-02-06 |
US20110171218A1 (en) | 2011-07-14 |
CA2782320A1 (fr) | 2011-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN05169A (fr) | ||
CY1118343T1 (el) | Αντισωματα συνδεσης twεακ | |
WO2012142515A3 (fr) | Protéines hybrides fc comprenant de nouveaux lieurs ou agencements | |
SG162687A1 (en) | Caustic stable chromatography ligands | |
CR20120371A (es) | Antagonistas de pcsk9 | |
EA201171148A1 (ru) | Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7 | |
CA2705357C (fr) | Formulations pour proteines hybrides taci-immunoglobuline | |
EP2333116A3 (fr) | Marqueurs de rejet de greffe de rein et de lésions rénales | |
WO2011047087A3 (fr) | Détection de protéine par l'intermédiaire de nanorapporteurs | |
WO2012139134A3 (fr) | Procédés de modulation des protéines de fusion oncogènes | |
MX2010000196A (es) | Prevencion de reduccion de enlaces de disulfuro durante la produccion recombinante de polipeptidos. | |
WO2013075066A3 (fr) | Protéines ayant une demi-vie et d'autres propriétés améliorées | |
MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
EP2516624A4 (fr) | Lignée cellulaire 3m | |
WO2008033408A3 (fr) | Procédés d'identification de composés qui modulent la signalisation cellulaire et procédés employant de tels composés | |
MX2010007716A (es) | Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas. | |
AR113492A2 (es) | Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla | |
WO2013052946A3 (fr) | Biocapteurs génétiquement codés | |
TR201911082T4 (tr) | K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem. | |
WO2012068317A3 (fr) | Procédés de production de protéines recombinantes | |
IN2012DN02073A (fr) | ||
CO6241120A2 (es) | (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS. | |
WO2008085900A3 (fr) | Procédé permettant de générer de nouvelles protéines stabilisées | |
EP3976642A4 (fr) | Anticorps apoe, protéines de fusion et leurs utilisations | |
EA201691532A1 (ru) | Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков |